Pacira BioSciences Inc

Pacira BioSciences insider buying signals confidence in its non‑opioid pipeline, with top execs buying RSUs and the stock rallying 3.7% amid a 46‑PP&E‑priced premium.

Pacira BioSciences insider sales reveal routine portfolio rebalancing, not a downturn, while PB‑01’s breakthrough, non‑opioid pain‑management potential fuels investor optimism.